**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 63482

**Manuscript Type:** ORIGINAL ARTICLE

***Case Control Study***

**Clinical significance of serum miR-129-5p in patients with diabetes mellitus presenting macrovascular complications**

He XY *et al*. Serum miR-129-5p and diabetic macrovascular complications

Xiao-Yun He, Chun-Lin Ou

**Xiao-Yun He, Chun-Lin Ou,** Department of Pathology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China

**Xiao-Yun He,** Department of Endocrinology, Affiliated Hospital of Guilin Medical University, Guilin 541001, Guangxi Zhuang Autonomous Region, China

**Author contributions:** He XY and Ou CL collected the data, drafted the manuscript, performed critical revision of the manuscript, and approved the final manuscript.

**Supported by** National Natural Science Foundation of China, No. 81903032; China Postdoctoral Science Foundation, No. 2020M672520; Research Program of Hunan Health Commission, China, No. 202103030659; and Youth Fund of Xiangya Hospital, No. 2018Q011.

**Corresponding author: Chun-Lin Ou, PhD, Academic Research,** Department of Pathology, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha 410008, Hunan Province, China. ouchunlin@csu.edu.cn

**Received:** January 28, 2021

**Revised:** May 24, 2021

**Accepted:** July 6, 2021

**Published online:**

**Abstract**

BACKGROUND

Diabetic macrovascular complications (DMCs) are the most common complications encountered during the course of diabetes mellitus (DM) with extremely high mortality rates. Therefore, there is an urgent need to identify specific and sensitive biomarkers for the early diagnosis of DMCs.

AIM

To investigate the expression and significance of serum miR-129-5p in patients with DM and macrovascular complications.

METHODS

Serum samples were collected from 36 healthy controls, 58 patients with DM presenting no macrovascular complications, and 62 patients with DMCs. The expression of miR-129-5p was detected using quantitative real-time polymerase chain reaction. Pearson’s correlation assay was performed to analyze the correlation between serum miR-129-5p levels and clinical indicators. Receiver operator characteristic (ROC) analysis was conducted to analyze the diagnostic value of serum miR-129-5p in patients with DM or DMCs.

RESULTS

There was a 4.378-fold and 7.369-fold increase in serum miR-129-5p expression in the DM (5.346 ± 0.405) and DMCs (8.998 ± 0.631) groups, respectively (*p* < 0.001), compared with the control group (1.221±0.090). In addition, the expression of serum miR-129-5p in patients with DMCs was higher than that in patients with DM, revealing a 1.683-fold increase (*p* < 0.001). Additionally, serum miR-129-5p expression significantly correlated with smoking history, disease duration, and glycated hemoglobin (HbA1c) in patients with DMCs (*p* < 0.001). The area under the ROC curve (AUC) of miR-129-5p as a serum marker was 0.964 (95% confidence interval [CI]: 0.930-0.997, *p* < 0.001) in distinguishing between patients with DM and healthy controls, whereas the AUC of miR-129-5p as a serum marker was 0.979 (95%CI: 0.959-0.999, *p* < 0.001) in distinguishing between patients with DMCs and healthy controls.

CONCLUSION

Elevated serum miR-129-5p expression levels correlate with the development of DMCs and can be utilized as a novel early diagnostic biomarker for DM combined with macrovascular complications.

**Key Words:** Diabetes mellitus; Diabetic macrovascular complications; MircoRNA; Diagnosis; Therapy

He XY, Ou CL. Clinical significance of serum miR-129-5p in patients with diabetes mellitus presenting macrovascular complications. *World J Diabetes* 2021; In press

**Core Tip:** Diabetic macrovascular complications (DMCs) are the most common complications encountered during the course of diabetes mellitus (DM) with extremely high mortality rates. Therefore, there is an urgent need to identify specific and sensitive biomarkers for the early diagnosis of DMCs. Here, we revealed that the high serum miR-129-5p expression is related to the development of DMCs and can be employed as a novel early diagnostic biomarker for DM combined with macrovascular complications.

**INTRODUCTION**

Diabetes mellitus (DM) is a metabolic disease characterized by chronic hyperglycemia and is considered one of the most common human diseases worldwide[1,2]. Long-term hyperglycemia may cause systemic vascular damage following the occurrence and development of DM, thereby inducing diabetic macrovascular complications (DMCs)[3-5]. DMCs are among the most critical factors related to DM-associated deaths, accounting for approximately 70% of mortalities[6,7]. Therefore, there is an urgent need to identify effective biomarkers for early diagnosis, monitoring progression, and targeted therapy of DMCs[8].

MicroRNAs (miRNAs) are a class of non-coding RNAs (ncRNAs) with a length of approximately 22 nucleotides, which are known to inhibit the expression of crucial molecules by binding to the untranslated region of target mRNA[2,9], thereby affecting the process of human metabolic diseases, including DM[10]. Moreover, miRNAs have been detected in tissues as well as in various body fluids, including blood, urine, saliva, and milk, especially in serum. Recently, accumulating evidence has revealed that serum miRNAs are closely associated with DM as well as DM-associated complications, such as DMCs. For example, Barutta *et al*[11] have demonstrated that serum miR-126 levels can be associated with vascular complications in DM. However, the patterns and role of a large number of serum miRNAs remain unclear.

In the present study, we aimed to detect changes in the serum expression of miR-129-5p in DM combined with DMCs and analyze the relationship between miR-129-5p expression and the clinical characteristics of DMCs, thus evaluating its potential as a novel biomarker for predicting the prognosis of DMCs.

**MATERIALS AND METHODS**

***Subjects and serum collection***

In total, 156 serum samples, including samples from 36 healthy controls, 58 patients with DM without DMCs, and 62 patients with DM presenting DMCs, were collected between March 2017 and January 2019 at the Affiliated Hospital of Guilin Medical University (Guilin, China). We used the most common clinical non-invasive examination, B-mode ultrasound, to diagnose patients with DM presenting macrovascular disease. If patients with DM presented carotid intimal thickening and atherosclerotic plaques on B-ultrasound examination, DM with a macrovascular disease was established. No patient presented with psychiatric disorders or other severe diseases. In addition, patient information, including patient's name, age, body mass index (BMI), duration of disease, systolic and diastolic pressures, oral glucose tolerance test (OGTT), glycated hemoglobin (hemoglobin A1c, HbA1c), and comprehensive metabolic indicators [*e.g.*, triglyceride (TG), total cholesterol (TCHO), high-density lipoprotein-cholesterol (HDL-c), and low-density lipoprotein-cholesterol (LDL-c)] were collected. Written informed consent was obtained from all patients and healthy controls.

Fasting venous blood samples (5 mL) were collected from all participants. After standing for 2 h, samples were centrifuged at 3500 rpm for 20 min at 4 °C; the obtained serum samples were transferred to freshly sterilized tubes and immediately stored at -80 °C.

***RNA extraction and quantitative real-time polymerase chain reaction***

Total RNA was extracted from serum specimens using a miRNA Serum/Plasma Isolation Kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Reverse transcription was performed using Mir-XTM miRNA First-Strand Synthesis Kit (Clontech, United States), and quantitative real-time polymerase chain reaction (qRT-PCR) assays were performed as described previously[12]. The relative expression of miR-129-5p was normalized to the expression of U6 and calculated using the comparative threshold cycle (Ct) method using the formula 2−ΔΔCt.

***Statistical analysis***

Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, Inc., San Diego, CA, United States) and SPSS 18.0 (IBM Corp., Chicago, IL, United States). Student’s *t*-test and one-way analysis of variance (ANOVA) were employed to evaluate the differential expression of serum miR-129-5p between patient groups and the healthy control group. Pearson’s correlation coefficient was utilized to analyze the correlation between two indicators. The relationship between clinical factors and miR-129-5p expression was estimated using the Chi-square test. Receiver-operating characteristic (ROC) curve analysis was performed using the SigmaPlot suite 13.0 software. Results with *P <* 0.05, *P <* 0.01, or *P <* 0.001 were deemed statistically significant.

**RESULTS**

***Comparison of general data***

Overall, no significant differences in age, sex, BMI, TCHO, or HDL-c were observed among the three groups. Data values for systolic pressure, diastolic pressure, OGTT, HbA1c, TG, and LDL-c in the DM and DMC groups were significantly higher than those in the control group (*P <* 0.05). Moreover, there was a 1.964-fold (*P <* 0.001) increase in the disease duration in the DMC group (10.560 ± 1.230 years), compared to that in the control group (5.376 ± 0.716 years); this finding was consistent with a previous study indicating that a DM duration of more than 5 years might induce DMCs more often[13].

***Serum miR-129-5p levels in patients with DM and DMCs and healthy controls***

Next, we used qRT-PCR to detect the differential expression of serum miR-129-5p in patients with DM presenting no DMCs, patients with DMCs, and healthy controls. There was a 4.378-fold and 7.369-fold increase in serum miR-129-5p expression in the DM (5.346 ± 0.405) and DMC (8.998 ± 0.631) groups, respectively, compared to the control group (1.221 ± 0.090; *P <* 0.001; Figure 1). Further analysis showed that serum miR-129-5p expression level in patients with DMCs was significantly higher than that in patients with DM, demonstrated as a 1.683-fold increase (*p* < 0.001, Figure 1).

***Correlation between serum expression of miR-129-5p and clinical factors in DM and DMCs***

Pearson’s correlation coefficient was employed to analyze the correlation between the expression of serum miR-129-5p and clinical variables in DM and DMCs. The results demonstrated that the expression of serum miR-129-5p positively correlated with OGTT (glucose 2 h after dinner) in patients with DM (*P <* 0.05, Table 1); however, in patients with DMCs, serum miR-129-5p expression positively correlated with the disease duration, smoking history, DM family history, fasting glucose (OGTT), and HbA1c (*P <* 0.05, Table 2). Our findings revealed that the serum expression of miR-129-5p was more closely related to the clinical factors of DMCs than those of DM, suggesting that serum miR-129-5p can serve as a potential molecular marker for detecting the development of DMCs.

***Clinical associations of serum miR-129-5p in patients with DMCs***

Based on the median serum level of miR-129-5p, patients with DM presenting DMCs were divided into high- and low-level groups. The relationship between the expression levels of serum miR-129-5p and clinical factors in DMCs was analyzed using the Chi-square test. As shown in Table 3, the expression levels of serum miR-129-5p showed no significant correlation with patient gender, age, family history of DM, high blood pressure, or fasting blood glucose (*p* > 0.05). However, serum miR-129-5p levels significantly correlated with smoking history, disease duration, and HbA1c in patients with DMCs (*P <* 0.05).

***Diagnostic value of serum miR-129-5p in patients with DMCs***

Furthermore, we performed ROC curve analysis to evaluate the diagnostic value of serum miR-129-5p as a serum marker in patients with DM lacking DMCs and patients with DMCs. The results revealed that the area under the ROC curve (AUC) of miR-129-5p as a serum marker was 0.964 (95%CI: 0.930-0.997, *P <* 0.001, Figure 2A) in distinguishing between patients with DM and healthy controls; the AUC of miR-129-5p as a marker was 0.979 (95%CI: 0.959-0.999, *P <* 0.001, Figure 2B) in distinguishing between patients with DMC and healthy controls. This result implied that the diagnostic value of serum miR-129-5p in patients with DMCs was higher than that in patients with DM.

**DISCUSSION**

DMCs are the most common complications associated with DM and are typically accompanied by pathological changes in endothelial cells, cardiomyocytes, vascular cells, and stem cells. The occurrence and development of DMCs involve various underlying mechanisms, including autophagy[14], oxidative stress[15], inflammatory response, and immune response[16]. In the present study, we revealed that the disease duration in the DMC group was significantly prolonged when compared with the DM group (*P <* 0.001), indicating that vascular complications are important factors in DM-related deaths. Therefore, there is considerable urgency in the search for early diagnostic markers and drug targets for DMCs.

With the development of RNA-seq and next-generation sequencing technologies[17,18], an increasing number of miRNAs have been discovered and identified to be strongly associated with the development of DM[19-21]. miRNAs are present in human plasma in a stable form, showing a higher specificity and sensitivity of detection than serum proteins. Therefore, serum miRNAs have been widely employed as novel diagnostic biomarkers for DM. To date, numerous serum miRNAs are found to be aberrantly expressed during DMCs, including miR-148[22], miR-342[23],and miR-133a[24], with a few recent studies elaborating the relationship between serum miRNAs and DMCs.

miR-129-5p is a member of the miRNA family and is closely related to the development and progression of human cancers[25,26]. Recently, miR-129-5p was found to regulate diabetic wound healing[27], DM-associated inflammatory response[28], and revascularization[29]. However, the patterns and role of high serum miR-129-5p expression in DMCs remain unclear. In the present study, we observed that serum expression of miR-129-5p was significantly higher in patients with DM and patients with DMCs than in the control group. Furthermore, the expression of serum miR-129-5p was significantly higher in patients with DMCs than that in patients with DM (*P <* 0.05). Further evaluation revealed that the expression of serum miR-129-5p correlated significantly with smoking history, disease duration, and HbA1c in patients with DMCs (all *P <* 0.001). Additionally, the AUC of miR-129-5p as a serum marker was 0.964 (95%CI: 0.930-0.997, *P <* 0.001) in distinguishing between patients with DM and healthy controls, whereas the AUC of miR-129-5p as a serum marker was 0.979 (95%CI: 0.959-0.999, *P <* 0.001) in distinguishing between patients with DMCs and healthy controls.

**CONCLUSION**

Collectively, our findings provide convincing evidence demonstrating the upregulation of serum miR-129-5p, which can serve as a novel molecular marker for the early diagnosis of DMCs. In addition, the expression of serum miR-129-5p significantly correlates with smoking history, disease duration, and HbA1c in patients with DMCs.

**ARTICLE HIGHLIGHTS**

***Research background***

Diabetic macrovascular complications (DMCs) are the most common complications encountered during the course of diabetes mellitus (DM) with extremely high mortality rates.

***Research motivation***

There is an urgent need to identify specific and sensitive biomarkers for the early diagnosis of DMCs.

***Research objectives***

To investigate the expression and significance of serum miR-129-5p in patients with DM and macrovascular complications.

***Research methods***

Serum samples were collected from 36 healthy controls, 58 patients with DM presenting no macrovascular complications, and 62 patients with DMCs. The expression of miR-129-5p was detected using quantitative real-time polymerase chain reaction. Pearson’s correlation assay was performed to analyze the correlation between serum miR-129-5p levels and clinical indicators. Receiver operator characteristic analysis was conducted to analyze the diagnostic value of serum miR-129-5p in patients with DM or DMCs.

***Research results***

These finding demonstrated that serum expression of miR-129-5p was significantly higher in patients with DM and patients with DMCs than in the control group. Furthermore, the expression of serum miR-129-5p was significantly higher in patients with DMCs than in patients with DM (*P <* 0.05). Further evaluation revealed that the expression of serum miR-129-5p correlated significantly with smoking history, disease duration, and HbA1c in patients with DMCs (*P <* 0.001). Additionally, the AUC of miR-129-5p as a serum marker was 0.964 (95%CI: 0.930-0.997, *P <* 0.001) in distinguishing between patients with DM and healthy controls, whereas the AUC of miR-129-5p as a serum marker was 0.979 (95%CI: 0.959-0.999, *P <* 0.001) in distinguishing between patients with DMCs and healthy controls.

***Research conclusions***

Elevated serum miR-129-5p expression levels correlate with the development of DMCs and can be utilized as a novel early diagnostic biomarker for DM combined with macrovascular complications.

***Research perspectives***

The high serum miR-129-5p expression is related to the development of DMCs and can be employed as a novel early diagnostic biomarker for DM combined with macrovascular complications.

**REFERENCES**

1 **Alegre-Díaz J**, Herrington W, López-Cervantes M, Gnatiuc L, Ramirez R, Hill M, Baigent C, McCarthy MI, Lewington S, Collins R, Whitlock G, Tapia-Conyer R, Peto R, Kuri-Morales P, Emberson JR. Diabetes and Cause-Specific Mortality in Mexico City. *N Engl J Med* 2016; **375**: 1961-1971 [PMID: 27959614 DOI: 10.1056/NEJMoa1605368]

2 **Liu B**, Wang Y, Zhang Y, Yan B. Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction. *Curr Top Med Chem* 2019; **19**: 1818-1849 [PMID: 31456521 DOI: 10.2174/1568026619666190828161409]

3 **Taylor SI**, Yazdi ZS, Beitelshees AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. *J Clin Invest* 2021; **131** [PMID: 33463546 DOI: 10.1172/JCI142243]

4 **Yehualashet AS**. Toll-like Receptors as a Potential Drug Target for Diabetes Mellitus and Diabetes-associated Complications. *Diabetes Metab Syndr Obes* 2020; **13**: 4763-4777 [PMID: 33311992 DOI: 10.2147/DMSO.S274844]

5 **Paul S**, Ali A, Katare R. Molecular complexities underlying the vascular complications of diabetes mellitus - A comprehensive review. *J Diabetes Complications* 2020; **34**: 107613 [PMID: 32505477 DOI: 10.1016/j.jdiacomp.2020.107613]

6 **Hink U**, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. *Circ Res* 2001; **88**: E14-E22 [PMID: 11157681 DOI: 10.1161/01.res.88.2.e14]

7 **Rao Kondapally Seshasai S**, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njølstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. *N Engl J Med* 2011; **364**: 829-841 [PMID: 21366474 DOI: 10.1056/NEJMoa1008862]

8 **Lysy PA**, Corritore E, Sokal EM. New Insights into Diabetes Cell Therapy. *Curr Diab Rep* 2016; **16**: 38 [PMID: 26983626 DOI: 10.1007/s11892-016-0729-3]

9 **Ou C**, Sun Z, Li X, Li X, Ren W, Qin Z, Zhang X, Yuan W, Wang J, Yu W, Zhang S, Peng Q, Yan Q, Xiong W, Li G, Ma J. MiR-590-5p, a density-sensitive microRNA, inhibits tumorigenesis by targeting YAP1 in colorectal cancer. *Cancer Lett* 2017; **399**: 53-63 [PMID: 28433598 DOI: 10.1016/j.canlet.2017.04.011]

10 **Rajkumar KV**, Lakshmanan G, Sekar D. Identification of miR-802-5p and its involvement in type 2 diabetes mellitus. *World J Diabetes* 2020; **11**: 567-571 [PMID: 33384764 DOI: 10.4239/wjd.v11.i12.567]

11 **Barutta F**, Bruno G, Matullo G, Chaturvedi N, Grimaldi S, Schalkwijk C, Stehouwer CD, Fuller JH, Gruden G. MicroRNA-126 and micro-/macrovascular complications of type 1 diabetes in the EURODIAB Prospective Complications Study. *Acta Diabetol* 2017; **54**: 133-139 [PMID: 27696070 DOI: 10.1007/s00592-016-0915-4]

12 **Ou C**, Sun Z, He X, Li X, Fan S, Zheng X, Peng Q, Li G, Li X, Ma J. Targeting YAP1/LINC00152/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer. *Adv Sci (Weinh)* 2020; **7**: 1901380 [PMID: 32042551 DOI: 10.1002/advs.201901380]

13 **Annani-Akollor ME**, Addai-Mensah O, Fondjo LA, Sallah L, Owiredu EW, Acheampong E, Akamugri S. Predominant Complications of Type 2 Diabetes in Kumasi: A 4-Year Retrospective Cross-Sectional Study at a Teaching Hospital in Ghana. *Medicina (Kaunas)* 2019; **55** [PMID: 31075814 DOI: 10.3390/medicina55050125]

14 **Xu J**, Kitada M, Ogura Y, Koya D. Relationship Between Autophagy and Metabolic Syndrome Characteristics in the Pathogenesis of Atherosclerosis. *Front Cell Dev Biol* 2021; **9**: 641852 [PMID: 33937238 DOI: 10.3389/fcell.2021.641852]

15 **Byrne NJ**, Rajasekaran NS, Abel ED, Bugger H. Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy. *Free Radic Biol Med* 2021; **169**: 317-342 [PMID: 33910093 DOI: 10.1016/j.freeradbiomed.2021.03.046]

16 **Navas-Madroñal M**, Castelblanco E, Camacho M, Consegal M, Ramirez-Morros A, Sarrias MR, Perez P, Alonso N, Galán M, Mauricio D. Role of the Scavenger Receptor CD36 in Accelerated Diabetic Atherosclerosis. *Int J Mol Sci* 2020; **21** [PMID: 33028031 DOI: 10.3390/ijms21197360]

17 **Armingol E**, Officer A, Harismendy O, Lewis NE. Deciphering cell-cell interactions and communication from gene expression. *Nat Rev Genet* 2021; **22**: 71-88 [PMID: 33168968 DOI: 10.1038/s41576-020-00292-x]

18 **Zheng T**, Ellinghaus D, Juzenas S, Cossais F, Burmeister G, Mayr G, Jørgensen IF, Teder-Laving M, Skogholt AH, Chen S, Strege PR, Ito G, Banasik K, Becker T, Bokelmann F, Brunak S, Buch S, Clausnitzer H, Datz C; DBDS Consortium, Degenhardt F, Doniec M, Erikstrup C, Esko T, Forster M, Frey N, Fritsche LG, Gabrielsen ME, Gräßle T, Gsur A, Gross J, Hampe J, Hendricks A, Hinz S, Hveem K, Jongen J, Junker R, Karlsen TH, Hemmrich-Stanisak G, Kruis W, Kupcinskas J, Laubert T, Rosenstiel PC, Röcken C, Laudes M, Leendertz FH, Lieb W, Limperger V, Margetis N, Mätz-Rensing K, Németh CG, Ness-Jensen E, Nowak-Göttl U, Pandit A, Pedersen OB, Peleikis HG, Peuker K, Rodriguez CL, Rühlemann MC, Schniewind B, Schulzky M, Skieceviciene J, Tepel J, Thomas L, Uellendahl-Werth F, Ullum H, Vogel I, Volzke H, von Fersen L, von Schönfels W, Vanderwerff B, Wilking J, Wittig M, Zeissig S, Zobel M, Zawistowski M, Vacic V, Sazonova O, Noblin ES; 23andMe Research Team, Farrugia G, Beyder A, Wedel T, Kahlke V, Schafmayer C, D'Amato M, Franke A. Genome-wide analysis of 944 133 individuals provides insights into the etiology of haemorrhoidal disease. *Gut* 2021 [PMID: 33888516 DOI: 10.1136/gutjnl-2020-323868]

19 **Price NL**, Goedeke L, Suárez Y, Fernández-Hernando C. miR-33 in cardiometabolic diseases: lessons learned from novel animal models and approaches. *EMBO Mol Med* 2021; **13**: e12606 [PMID: 33938628 DOI: 10.15252/emmm.202012606]

20 **Bali KK**, Gandla J, Rangel DR, Castaldi L, Mouritzen P, Agarwal N, Schmelz M, Heppenstall P, Kuner R. A genome-wide screen reveals microRNAs in peripheral sensory neurons driving painful diabetic neuropathy. *Pain* 2021; **162**: 1334-1351 [PMID: 33492037 DOI: 10.1097/j.pain.0000000000002159]

21 **Hua F**. New insights into diabetes mellitus and its complications: a narrative review. *Ann Transl Med* 2020; **8**: 1689 [PMID: 33490201 DOI: 10.21037/atm-20-7243]

22 **Grieco GE**, Cataldo D, Ceccarelli E, Nigi L, Catalano G, Brusco N, Mancarella F, Ventriglia G, Fondelli C, Guarino E, Crisci I, Sebastiani G, Dotta F. Serum Levels of miR-148a and miR-21-5p Are Increased in Type 1 Diabetic Patients and Correlated with Markers of Bone Strength and Metabolism. *Noncoding RNA* 2018; **4** [PMID: 30486455 DOI: 10.3390/ncrna4040037]

23 **Eissa S**, Matboli M, Bekhet MM. Clinical verification of a novel urinary microRNA panal: 133b, -342 and -30 as biomarkers for diabetic nephropathy identified by bioinformatics analysis. *Biomed Pharmacother* 2016; **83**: 92-99 [PMID: 27470555 DOI: 10.1016/j.biopha.2016.06.018]

24 **de Gonzalo-Calvo D**, van der Meer RW, Rijzewijk LJ, Smit JW, Revuelta-Lopez E, Nasarre L, Escola-Gil JC, Lamb HJ, Llorente-Cortes V. Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. *Sci Rep* 2017; **7**: 47 [PMID: 28246388 DOI: 10.1038/s41598-017-00070-6]

25 **Cao J**, Shen Y, Zhu L, Xu Y, Zhou Y, Wu Z, Li Y, Yan X, Zhu X. miR-129-3p controls cilia assembly by regulating CP110 and actin dynamics. *Nat Cell Biol* 2012; **14**: 697-706 [PMID: 22684256 DOI: 10.1038/ncb2512]

26 **Chen X**, Ruan A, Wang X, Han W, Wang R, Lou N, Ruan H, Qiu B, Yang H, Zhang X. miR-129-3p, as a diagnostic and prognostic biomarker for renal cell carcinoma, attenuates cell migration and invasion *via* downregulating multiple metastasis-related genes. *J Cancer Res Clin Oncol* 2014; **140**: 1295-1304 [PMID: 24802708 DOI: 10.1007/s00432-014-1690-7]

27 **Wang W**, Yang C, Wang XY, Zhou LY, Lao GJ, Liu D, Wang C, Hu MD, Zeng TT, Yan L, Ren M. MicroRNA-129 and -335 Promote Diabetic Wound Healing by Inhibiting Sp1-Mediated MMP-9 Expression. *Diabetes* 2018; **67**: 1627-1638 [PMID: 29748291 DOI: 10.2337/db17-1238]

28 **Umehara T**, Mori R, Mace KA, Murase T, Abe Y, Yamamoto T, Ikematsu K. Identification of Specific miRNAs in Neutrophils of Type 2 Diabetic Mice: Overexpression of *miRNA-129-2-3p* Accelerates Diabetic Wound Healing. *Diabetes* 2019; **68**: 617-630 [PMID: 30523028 DOI: 10.2337/db18-0313]

29 **Ma XL**, Li SY, Shang F. Effect of microRNA-129-5p targeting HMGB1-RAGE signaling pathway on revascularization in a collagenase-induced intracerebral hemorrhage rat model. *Biomed Pharmacother* 2017; **93**: 238-244 [PMID: 28645008 DOI: 10.1016/j.biopha.2017.06.012]

**Footnotes**

**Institutional review board statement:** This study was reviewed and approved by the Medical Ethics Committee of the Affiliated Hospital of Guilin Medical University.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors declare no conflicts of interest for this manuscript.

**Data sharing statement:** The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

**STROBE statement:** The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 28, 2021

**First decision:** April 6, 2021

**Article in press:**

**Specialty type:** Cardiac and cardiovascular systems

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B


Grade C (Good): 0

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Aureliano M, Hussein A, Spartalis M **S-Editor:** Ma YJ **L-Editor:** Wang TQ **P-Editor:**

**Figure Legends**



**Figure 1 The expression levels of serum miR-129-5p in healthy controls and in patients with diabetes mellitus and diabetic macrovascular complications.** Data are presented as the mean ± SE. b*P <* 0.001, *vs* control. DM: diabetes mellitus; DMCs: diabetic macrovascular complications.



**Figure 2** **Receiver-operating characteristic curve analysis to analyze the potential of miR-129-5p as a serum marker for patients with diabetes mellitus or patients with diabetic macrovascular complications.** A and B: Receiver-operating characteristic curves displaying sensitivity and specificity of serum miR-129-5p to diagnose patients with diabetes mellitus (A) or patients with diabetic macrovascular complications (B). Insets indicate the area under the curve values, 95% confidence intervals, and statistics. DM: diabetes mellitus; DMCs: diabetic macrovascular complications; AUC: Area under the curve; ROC: Receiver-operating characteristic.

**Table 1 Baseline characteristics of all participants**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Control (*n* = 36)** | **DM (*n* = 58)** | **DMC (*n* = 62)** |
| **Age (yr)** | 53.310 ± 1.535 | 55.860 ± 1.400 | 57.050 ± 1.190 |
| **Gender (male/female)** | (13/23) | (32/26) | (33/29) |
| **BMI (kg/m2)** | 24.150 ± 0.306 | 24.660 ± 0.388 | 25.050 ± 0.305 |
| **Duration of disease (yr)** | - | 5.376 ± 0.716 | 10.560 ± 1.230e |
| **Systolic pressure (mmHg)** | 123.510 ± 2.039 | 134.703 ± 2.456b | 137.712 ± 2.497c |
| **Diastolic pressure (mmHg)** | 73.081 ± 1.704 | 82.261 ± 1.471c | 81.732 ± 1.349c |
| **OGTT (mmol/L)** |  |  |  |
| Fasting glucose | 5.397 ± 0.051 | 11.511 ± 0.597c | 11.341 ± 0.709c |
| 1-h glucose | 8.835 ± 0.094 | 13.763 ± 0.596c | 13.113 ± 0.339c |
| 2-h glucose | 6.568 ± 0.108 | 14.061 ± 0.622c | 13.650 ± 0.483c |
| **HbA1c, (%)** | 5.589 ± 0.111 | 10.64 ± 0.323c | 10.290 ± 0.287c |
| **Comprehensive metabolic indicators** | |  |  |
| TG (mmol/L) | 1.335 ± 0.121 | 2.265 ± 0.2483b | 1.867 ± 0.154a |
| TCHO (mmol/L) | 4.792 ± 0.208 | 4.986 ± 0.153 | 5.047 ± 0.205 |
| HDL-c (mmol/L) | 1.410 ± 0.060 | 1.312 ± 0.049 | 1.303 ± 0.043 |
| LDL-c (mmol/L) | 2.831 ± 0.1643 | 3.566 ± 0.188b | 3.735 ± 0.227b |

a*P <* 0.05, b*P <* 0.01, c*P <* 0.001,*vs* control; e*P <* 0.001, *vs* diabetes mellitus. DM: diabetes mellitus; DMC: Diabetic macrovascular complication; BMI: body mass index; OGTT: oral glucose tolerance test; HbA1c: hemoglobin A1c; TG: triglyceride; TCHO: total cholesterol; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol.

**Table 2 Correlation between the expression of serum miR-129-5p and clinical factors in diabetes mellitus and diabetic macrovascular complications**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **DM** | | |  | **DMV** | | |
| ***r*** | ***p* value** | |  | ***r*** | | ***P* value** |
| **Age (yr)** | 0.205 | | 0.122 |  | 0.240 | 0.060 | |
| **Gender** | -0.025 | | 0.850 |  | -0.178 | 0.167 | |
| **BMI (kg/m2)** | -0.193 | | 0.146 |  | -0.069 | 0.597 | |
| **Duration of disease (yr)** | 0.122 | | 0.361 |  | 0.335 | 0.008 | |
| **Smoking history** | -0.135 | | 0.312 |  | 0.346 | 0.006 | |
| **DM family history** | -0.060 | | 0.656 |  | 0.299 | 0.018 | |
| **Systolic pressure, mmHg** | -0.133 | | 0.318 |  | -0.136 | 0.290 | |
| **Diastolic pressure, mmHg** | -0.190 | | 0.153 |  | -0.191 | 0.137 | |
| **OGTT (mmol/L)** |  | |  |  |  |  | |
| Fasting glucose | 0.111 | | 0.405 |  | 0.268 | 0.036 | |
| 1-h glucose | 0.258 | | 0.050 |  | 0.071 | 0.582 | |
| 2-h glucose | 0.283 | | 0.031 |  | 0.183 | 0.154 | |
| **HbA1c, %** | 0.149 | | 0.263 |  | 0.255 | 0.045 | |
| TG | -0.149 | | 0.263 |  | -0.176 | 0.172 | |
| CHOL | -0.057 | | 0.673 |  | 0.138 | 0.285 | |
| HDL-c | -0.052 | | 0.696 |  | -0.105 | 0.418 | |
| LDL-c | -0.115 | | 0.389 |  | -0.105 | 0.417 | |

DM: diabetes mellitus; DMC: Diabetic macrovascular complication; BMI: body mass index; OGTT: oral glucose tolerance test; HbA1c: hemoglobin A1c; TG: triglyceride; TCHO: total cholesterol; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol.

**Table 3 Relationship between the expression of serum miR-129-5p and clinical factors in diabetic macrovascular complications**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Parameter** | **No. of cases (*n* = 62)** | | | **miR-129 level** | | | | | | ***χ*2** | | | | | ***P-*Value** |
| **High (*n* = 24)** | | | | **Low (*n* = 38)** | |
| **Gender** |  | |  | | | |  | | |  | | | | |  |
| Male | 33 | | | | | 15 | | 18 | | 1.353 | | | | 0.245 | |
| Female | 29 | | | | | 9 | | 20 | |
| **Age (**yr**)** |  | | | | |  | |  | |  | | | |  | |
| ≥ 60 | 31 | | | | | 15 | | 16 | | 2.447 | | | | 0.118 | |
| < 60 | 31 | | | | | 9 | | 22 | |
| **BMI (kg/m2)** |  |  | | | |  | | |  | |  | | | | |
| ≥ 24 | 42 | | | | | 13 | | | 29 | | 3.302 | 0.069 | | | |
| 0 < 24 | 20 | | | | | 11 | | | 9 | |
| **Smoking history** |  |  | | | |  | | |  | |  | | | | |
| Yes | 16 | | | | | 10 | | 6 | | 5.144 | | | 0.023 | | |
| No | 46 | | | | | 14 | | 32 | |
| **DM family history** | | | | | | | | | | | | | | | |
| Yes | 25 | | | | 13 | | | 12 | | 3.119 | | 0.077 | | | |
| No | 37 | | | | 11 | | | 26 | |
| **Duration of disease (yr)** |  | | | |  | | |  | |  | |  | | | |
| ≥ 10 | 29 | | | | 16 | | | 13 | | 6.224 | | 0.013 | | | |
| < 10 | 33 | | | | 8 | | | 25 | |
| **HBP** |  | | | |  | | |  | |  | |  | | | |
| Yes | 28 | | | | 12 | | | 16 | | 0.370 | | 0.543 | | | |
| No | 34 | | | | 12 | | | 22 | |
| **HbA1c (%)** |  | | | |  | | |  | |  | |  | | | |
| ≥ 10 .28 | 33 | | | | 18 | | | 15 | | 7.457 | | 0.006 | | | |
| < 10.28 | 29 | | | | 6 | | | 23 | |
| **FBG (mmol/L)** |  | | | |  | | |  | |  | |  | | | |
| ≥ 10 .34 | 21 | | | | 10 | | | 11 | | 1.062 | | 0.303 | | | |
| < 10.34 | 41 | | | | 14 | | | 27 | |
| **PBS 1 h (mmol/L)** |  | | | |  | | |  | |  | |  | | | |
| ≥ 13.11 | 36 | | | | 15 | | | 21 | | 0.316 | | 0.574 | | | |
| < 13.11 | 26 | | | | 9 | | | 17 | |
| **PBS 2 h (mmol/L)** |  | | | |  | | |  | |  | |  | | | |
| ≥ 13.65 | 33 | | | | 14 | | | 19 | | 0.410 | | 0.522 | | | |
| < 13.65 | 29 | | | | 10 | | | 19 | |
| **TG (mmol/L)** |  | | | |  | | |  | |  | |  | | | |
| ≥ 1.867 | 20 | | | | 5 | | | 15 | | 2.339 | | 0.126 | | | |
| < 1.867 | 42 | | | | 19 | | | 23 | |
| **TCHO (mmol/L)** |  | | | |  | | |  | |  | |  | | | |
| ≥ 5.047 | 24 | | | | 9 | | | 15 | | 0.024 | | 0.876 | | | |
| < 5.047 | 38 | | | | 15 | | | 23 | |
| **HDL-c (mmol/L)** |  | | | |  | | |  | |  | |  | | | |
| ≥ 1.303 | 30 | | | | 10 | | | 20 | | 0.708 | | 0.400 | | | |
| < 1.303 | 32 | | | | 14 | | | 18 | |
| **LDL-c (mmol/L)** |  | | | |  | | |  | |  | |  | | | |
| ≥ 3.735 | 27 | | | | 11 | | | 16 | | 0.083 | | 0.773 | | | |
| < 3.735 | 35 | | | | 13 | | | 22 | |

BMI: body mass index; DM: diabetes mellitus; OGTT: oral glucose tolerance test; HbA1c: hemoglobin A1c; TG: triglyceride; TCHO: total cholesterol; HDL-c: high-density lipoprotein-cholesterol; LDL-c: low-density lipoprotein-cholesterol.